

Mikkel Bring Christensen
MD PhD, Ledende overlæge
Klinisk Farmakologisk Afdeling BFH
Center for Translationel Forskning BFH
Adresstype: Postadresse.
Danmark
E-mail: mikkel.bring.christensen@regionh.dk
Email: Mikkel.Bring.Christensen@regionh.dk
Telefon: 38635593



Education

2004: Master of Medicine, University of Copenhagen, Denmark and authorization as a physician; 2006: Permission to practice independently as a physician (full registration); 2013: Specialist in Clinical Pharmacology (aut. ID: 05HN6), The Danish National Board of Health; 2014: PhD in health science (Thesis ISBN: 978-87-92613-44-8), University of Copenhagen; 2016: Leadership Programme (6 modules, 14 days), Capital Region of Denmark; 2021: Research Management Course (6 modules, 9½ days), CBS Executive Fonden.

Employment History

2004: Resident, Department of Internal Medicine, Koege Hospital, University of Copenhagen, Denmark; 2004-2005: Resident, Department of Orthopedic Surgery, Koege Hospital, University of Copenhagen, Denmark; 2005-2005: GP resident, Solroed Strand, Denmark; 2006-2007: Several short term GP resident positions, Various places in Norway; 2006-2007: Resident physician, Department of Internal Medicine F, Gentofte Hospital University of Copenhagen, Denmark; 2007-2008: Resident physician, Department of Internal Medicine, Amager Hospital University of Copenhagen, Denmark; 2007-2008: Physician, Senior Resident, Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Denmark; 2008-2016: Medical Expert in authorization of medicinal products (10 hours weekly), Danish Medicines Agency; 2009-2010: Clinical Research Assistant, Center for Diabetes Research, Gentofte University Hospital; 2010: Physician, Senior Resident, Department of Hematology, Rigshospitalet, University of Copenhagen, Denmark; 2010-2012: Clinical Research Assistant, Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Denmark; 2012-2013: Physician, Senior Resident, Department of Clinical Pharmacology, Bispebjerg Hospital; 2013-2013: Physician, Senior Resident, Department of Internal Medicine, Gentofte Hospital; 2013-present: Chief Physician, Head of Education, Department of Clinical Pharmacology, Bispebjerg Hospital; 2013-present: Clinical Associate Professor, University of Copenhagen and Bispebjerg Hospital; 2018-present: Postgraduate Associate Professor, Eastern Region of Denmark & University of Copenhagen; 2020-present: Head of Copenhagen Centre for Translationel Research, Bispebjerg and Frederiksberg Hospital.

Current Positions

Head of Copenhagen Centre for Translational Research (60% position at Department of Biochemistry Bispebjerg and Frederiksberg Hospital) & Chief Physician and Clinical Associate Professor (40% position at the Department of Clinical Pharmacology, Bispebjerg Hospital). Responsibilities include Research management of translational research and phase one clinical trials (Zelo Phase one trial unit), medication reviews at outpatient clinics, function as a clinical toxicologist on-call at the national poison information center (Giftlinjen).

Honorary Positions

Dr. Mikkel Christensen is involved in several national and regional councils that evaluate pharmacotherapy and thereby impact rational use of medicines in Denmark. Ongoing from 2014: Chairman of the endocrinology group by the Capital Region's Medicines Committee (Den Regionale Lægemedjelkomite). Ongoing from 2016: Part of working group National Recommendation List (Den Nationale Rekommandationsliste) from the Danish Health Authority (Sundhedsstyrelsen) appointed by Danish Society of Clinical Pharmacology. From 2019: Member of the national Danish Medicines Council (Medicinerådet) "workgroup on type 2 diabetes" appointed by Danish Society of Clinical Pharmacology.

Recent Selected Awards and Grants

Awards: Awarded talent price from the Bagger-Sørensen foundation (2015), Young investigator of the year, Scandinavian Society for the Study of Diabetes (2012); Grants: Research grants from the Capital region of Denmark, University of Copenhagen, Danish Diabetes Association, Beckett-foundation and Tryg Foundation - total funding amounting to > € 2,000,000.

Publications, Citations and H-Indices

Research primarily within the areas: Clinical pharmacology, polypharmacy, medication review, diabetology, and medicines safety/toxicology (see full publication list on Google Scholar: Mikkel Christensen). Author of several textbook chapters and >120 scientific publications (68 original articles, 34 scientific reviews/proceedings, 25 commentaries/editorials/letters/case reports). >100 Danish and international scientific presentations. Impact Citations: ~ Citations: ~ 4279 (Google Scholar), ~2.671 (Web of Science). H-indices: 30 (Google Scholar), 29 (Web of Science); Scopus Author ID: 32067543900; ResearcherID: H-5861-2013; <https://orcid.org/0000-0002-8774-1797>

Supervising, Evaluation and Teaching Experience

Supervisor for 17 PhD students - 4 as primary supervisor (1 completed) and 13 as co-supervisor (4 completed) in clinical pharmacology, metabolism and toxicology. Extensive pre- and postgraduate teaching experience in physiology, pharmacology, toxicology and diabetology. Since 2013 clinical associate professor responsible for lectures, teaching and examination at University of Copenhagen course in clinical pharmacology (30 hours annually).

Summary of Own Research

Ongoing since 2008, I have been an active researcher in topics relating to clinical metabolism and pharmacology. My metabolic research has contributed significantly to understanding the action of endogenous hormones in diabetes and postprandial metabolism, particularly glucose and bone homeostasis and appetite regulation in humans. I am currently exploring interventions to avoid hypoglycemia in patients with diabetes. My research has among other things led to a patent (WO2016034186A1) that is currently investigated as treatment against obesity and other metabolic disorders. Since 2013 I have described various aspects and challenges with polypharmacy and how to deal with this by revising medication lists (Medication reviews). In 2017, I obtained funding to and initiated the Polypharmacy Outpatient Clinic at Bispebjerg and Frederiksberg Hospital. This clinic is now responsible for reviewing medications in complex patients with multiple diseases and pharmacological treatments and have shown great results with regards to improvements in pharmacotherapy and health-related quality of life (results awaiting publication).

Publikationer

Glucose-dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes-A randomised placebo-controlled study

Hoe, B., Heimbürger, S. M. N., Gasbjerg, L. S., Lanng, A. R., Lynggaard, M. B., Lund, A. B., Dela, F., Faber, J., Skov-Jepesen, K., Engberg, S., Hartmann, B., Holst, J. J., Vilsbøll, T., Christensen, M. B., Dejgaard, T. F. & Knop, F. K., mar. 2026, I: *Diabetes, Obesity and Metabolism*. 28, 3, s. 1886-1898 13 s.

The separate and combined effects of GIP, GLP-1 and GLP-2 on markers of bone turnover in type 2 diabetes

Hansen, J. V., Mathiesen, D. S., Christensen, M. B., Jørgensen, N. R., Helsted, M. M., Bagger, J. I., Holst, J. J., Vilsbøll, T., Knop, F. K. & Lund, A. B., 20 feb. 2026, I: *The Journal of clinical endocrinology and metabolism*. 111, 3, s. e853-e859

Glucose-Dependent Effects of Exogenous Glucagon-Like Peptide-2 on Circulating Glucagon Levels in Healthy Men

Sørum, N. E., Magnussen, T., Hansen, N. L., Nielsen, C. K., Holst, J. J., Hartmann, B., Henriksen, K., Størling, J., Faber, J., Christensen, M. B., Lund, A. B. & Knop, F. K., 1 feb. 2026, I: *Journal of the Endocrine Society*. 10, 2, s. bvaf215-bvaf215.

Identifying 20 homogeneous clusters of acute patients discharged with nonspecific diagnoses through k-prototypes mixed data clustering

Gregersen, R., Villumsen, M., Nyström, A., Nygaard, H., Rasmussen, J., Christensen, M. B., Forberg, J. L. & Petersen, J., 10 jan. 2026, (E-pub ahead of print) I: *BMC Emergency Medicine*. 44.

Intravenous Arginine Stimulates Glucagon Secretion More Than Equimolar Alanine, Leucine, Glutamine, and Proline in Humans

Suppli, M. P., Høgedal, A., Bagger, J. I., Grøndahl, M. F. G., Forman, J. L., Trammell, S. A. J., Vranešević, A., Grevengoed, T. J., Vilstrup, H., Christensen, M. B., Wewer Albrechtsen, N. J., Lund, A. B., Holst, J. J. & Knop, F. K., 1 okt. 2025, I: *Journal of the Endocrine Society*. 9, 10, s. bvaf139-bvaf139.

Effects of a six-week continuous s.c. infusion of GIP alone or in combination with once-weekly s.c. semaglutide on bone turnover markers

Fonnesbech-Wulf, C., Helsted, M. M., Schaltz, N. L., Lund, I. W., Forman, J. L., Nielsen, C., Englund, A., Hartmann, B., Vilsbøll, T., Holst, J. J., Lund, A. B., Christensen, M. B., Knop, F. K. & Gasbjerg, L. S., okt. 2025, I: *Diabetologia*. 68, suppl 1, s. S674-LBA 55.

Six-week continuous s.c. infusion of GIP alone or added to semaglutide treatment had no effect on mean glucose levels or body weight in individuals with type 2 diabetes

Helsted, M. M., Fønnesbech-Wulf, C., Schantz, N. L., Lund, I. W., Forman, J., Nielsen, C. K., Englund, A., Hartmann, B., Vilsbøll, T., Holst, J. J., Lund, A. B., Christensen, M. B., Knop, F. K. & Gasbjerg, L. S., sep. 2025, I: *Diabetologia*. 68, Suppl 1, s. S44-77.

The glucagonotropic effect of glucose-dependent insulinotropic polypeptide is negated during insulin-induced hypoglycaemia in persons with type 1 diabetes

Sørum, N. E., Nielsen, J. V. W., Holst, J. J., Hartmann, B., Gasbjerg, L. S., Størling, J., Dejgaard, T. F., Christensen, M. B., Campbell, J. E., Knop, F. K. & Lund, A. B., sep. 2025, I: *Diabetologia*. 68, Suppl 1, s. S51-91.

25 forskere og læger: Der er et påtrængende behov for en national strategi for forskning i ældres sundhed

Suëta, C. A., Helge, J. W., Schultz, M., Waldorf, F. B., Holm, E. A., Christensen, M. B., Kjaer, M., Linneberg, A., Sørensen, T. L., Overgaard, S., Møller, T., Holm, A., Kristiansen, M., Tetens, I., Hansen, J. P., Eiken, P., Kristensen, M. T., Nielsen, D. S., Kayser, L. & Zebis, M. K. & 5 flere, Kruuse, C. R., Jespersen, A. P., Scheibye-Knudsen, M., Beck, A. M. & Jørgensen, N. R., 18 aug. 2025, I: *Altinget*.

GIP Alone or with GLP-1RA Had No Detectable Effect on Glucose Levels in Individuals with Type 2 Diabetes

Helsted, M. M., Fønnesbech-Wulff, C. C., Schantz, N. L., Lund, I. W., Forman, J., Nielsen, C. K., Englund, A., Hartmann, B., Vilsbøll, T., Holst, J. J., Lund, A. B., Christensen, M. B., Knop, F. K. & Gasbjerg, L. S., jun. 2025, I: *Diabetes*. 74, Suppl 1, 2 s.

Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review

Korsholm, C., Bülow, C., Christensen, M., Dalhoff, K., Feinberg, J. B., Lund, T. M., Niemann, C. U., Petersen, T. S. & Andersen, M. A., feb. 2025, I: *Leukemia and Lymphoma*. 66, 2, s. 229-239 11 s.

The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin-A Randomized, Controlled, Crossover Study

Stuhr, L. K., Feinberg, J. B., Christoffersen, T., Dimopoulos, K., Christensen, M. B., Sonne, D. P., Riis, T., Plomgaard, P. S., Goetze, J. P., Larsen, E. L. & Karstoft, K., jan. 2025, I: *Clinical and Translational Science*. 18, 1, e70113.

Increasing Medication Use and Polypharmacy in Type 2 Diabetes: The Danish Experience From 2000 to 2020

Johansson, K. S., Jimenez Solem, E., Petersen, T. S. & Christensen, M. B., 1 dec. 2024, I: *Diabetes spectrum : a publication of the American Diabetes Association*. 47, 12, s. 2120-2127 8 s.

Secretin infusion decreases food intake in healthy men - a randomized, placebo-controlled, double-blind, crossover study

Heimbürger, S. M. N., Bentzen, M. J., Kizilkaya, H. S., Hartmann, B., Holst, J. J., Rosenkilde, M. M., Dela, F., Hansen, S. H., Rehfeld, J. F., Christensen, M. B. & Knop, F. K., dec. 2024, I: *European Journal of Endocrinology*. 191, 6, s. 545-557 13 s.

Patients' knowledge of the indications for their medications - a scoping review

Bülow, C., Clausen, S. S., Thøgersen, P. L., Dalin, D. A., Hansen, J. M., Johansson, K. S., Lundh, A. & Christensen, M. B., 8 okt. 2024, I: *BMC Health Services Research*. 24, 1, s. 1195-1195.

Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis

Grøndahl, M. F. G., Lange, A. H., Suppli, M. P., Bagger, J. I., Thing, M., Gluud, L. L., Kofod, D. H., Hornum, M., Van Hall, G., Trammell, S. A. J., Grevengoed, T. J., Hartmann, B., Holst, J. J., Vilsbøll, T., Christensen, M. B., Lund, A. B. & Knop, F. K., 1 okt. 2024, I: *Diabetes*. 73, 10, s. 1641-1647 7 s.

Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes-Related Outcomes, Adverse Events, and Medication Expenses

Johansson, K. S., Jimenez-Solem, E., Petersen, T. S. & Christensen, M. B., sep. 2024, I: *Diabetes Care*. 47, 9, s. 1656-1663 8 s.

Safety of native glucose-dependent insulinotropic polypeptide in humans

Halsted, M. M., Schaltz, N. L., Gasbjerg, L. S., Christensen, M. B., Vilsbøll, T. & Knop, F. K., jul. 2024, I: *Peptides*. 177, s. 171214-171214.

Farmakologisk behandling af type 2-diabetes i almen praksis med fokus på fremtidig tilskudsstatus for glukosesænkende lægemidler

Halmsted Olsen, J. H., Christensen, M. B., Brønden, A., Karstoft, K., Kristensen, J. K. & Glintborg, D., jun. 2024, I: *Rationel farmakoterapi* [online]. 2024, 3

Acute patients discharged without an established diagnosis: risk of mortality and readmission of nonspecific diagnoses compared to disease-specific diagnoses

Gregersen, R., Villumsen, M., Mottlau, K. H., Maule, C. F., Nygaard, H., Rasmussen, J. H., Christensen, M. B. & Petersen, J., 19 apr. 2024, I: *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*. 32, 1, s. 32-32.

Treatment of nausea in hospitalized patients with acute illness

Nersesjan, M., Nersesjan, S. C., Pedersen, L. & Christensen, M. B., 15 apr. 2024, I: *Ugeskrift for Læger*. 186, 16

Signs of Glucagon Resistance After a 2-Week Hypercaloric Diet Intervention

Suppli, M. P., Høgedal, A., Bagger, J. I., Chabanova, E., van Hall, G., Forman, J. L., Christensen, M. B., Albrechtsen, N. J. W., Holst, J. J. & Knop, F. K., 1 apr. 2024, I: *The Journal of clinical endocrinology and metabolism*. 109, 4, s. 955-967 13 s.

The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity

Grøndahl, M. F. G., Bagger, J. I., Suppli, M. P., van Hall, G., Albrechtsen, N. J. W., Holst, J. J., Vilsbøll, T., Christensen, M. B., Lund, A. B. & Knop, F. K., 1 mar. 2024, I: *Endocrine Connections*. 13, 3, e230516.

The development of type 2 diabetes management in people with severe mental illness in the Capital Region of Denmark from 2001 to 2015

Bakkedal, C., Persson, F., Christensen, M. B., Kriegbaum, M., Mohr, G. H., Andersen, J. S., Lind, B. S., Lykkegaard, C., Siersma, V. & Rozing, M. P., mar. 2024, I: *Acta Psychiatrica Scandinavica*. 149, 3, s. 219-233 15 s.

Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial

Holm-Weber, T., Skov, F., Mohanakumar, S., Thorup, L., Riis, T., Christensen, M. B., Sonne, D. P., Jensen, P. B., Bødtkjer, D. B. & Hjortdal, V. E., 2 jan. 2024, I: *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery*. 65, 1, s. 1-9 9 s., ezad380.

Non-Insulin Parenteral Therapies

Vilsbøll, T., Christensen, M. B., Andersen, A. & Knop, F. K., jan. 2024, *Textbook of Diabetes, 6th Edition*. Holt, R. I. G. & Flyvbjerg, A. (red.). Wiley-Blackwell, s. 520-533 14 s.

The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalized patients with COVID-19 in the capital region of Denmark

Kliim-Hansen, V., Johansson, K. S., Gasbjerg, L. S., Jimenez-Solem, E., Petersen, T. S., Nyeland, M. E., Winther-Jensen, M., Ankarfeldt, M. Z., Pedersen, M. G., Ellegaard, A.-M., Knop, F. K. & Christensen, M. B., jan. 2024, I: *Diabetes, Obesity and Metabolism*. 26, 1, s. 160-168 9 s.

The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects

Jensen, T. L., Brønden, A., Christensen, M. B., Karstoft, K. & Sonne, D. P., 2024, I: *Patient Preference and Adherence*. 18, s. 373-382 10 s.

The separate and combined effects of glucose-dependent insulinotropic polypeptide and alanine on plasma glucose during fasting in healthy individuals

Thomas, A. M., Warnøe, J. V., Mathiesen, D. S., Preskou, E. M., Dejgaard, T. F., Lund, A., Størling, J., Christensen, M. B., Gasbjerg, L. S. & Knop, F. K., 2024, I: *Diabetologia*. 67, Suppl 1, 539.

Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020

Johansson, K. S., Bülow, C., Jimenez-Solem, E., Petersen, T. S. & Christensen, M. B., dec. 2023, I: *The Lancet Healthy Longevity*. 4, 12, s. e685-e692

Impact of multimorbidity and polypharmacy on mortality after cancer: a nationwide registry-based cohort study in Denmark 2005-2017

Thomsen, M. K., Løppenthin, K. B., Bidstrup, P. E., Andersen, E. W., Dalton, S., Petersen, L. N., Pappot, H., Mortensen, C. E., Christensen, M. B., Frølich, A., Lassen, U. & Johansen, C., dec. 2023, I: *Acta Oncologica*. 62, 12, s. 1653-1660 8 s.

Medication changes implemented during medication reviews and factors related to deprescribing: Posthoc analyses of a randomized clinical trial in geriatric outpatients with polypharmacy

Kornholt, J., Feizi, S. T., Hansen, A. S., Laursen, J. T., Johansson, K. S., Reuther, L. Ø., Petersen, T. S., Pressel, E. & Christensen, M. B., nov. 2023, I: *British Journal of Clinical Pharmacology*. 89, 11, s. 3291-3301 11 s.

Methodological Considerations for Describing Medication Changes in Relation to Clinical Events and Death: An Applied Example in Patients with Type 2 Diabetes and Cancer

Johansson, K. S., Petersen, T. S., Christensen, M. B. & Pottegård, A., nov. 2023, I: *Drugs & Aging*. 40, 11, s. 1009-1015 7 s.

Mediceringennemgange? Ja tak, men hvor og hvordan?

Christensen, M. B., Bülow, C. & Lundh, A., 16 okt. 2023, I: *Ugeskrift for Læger*. 185:V205151.

The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalised patients with COVID-19 in the capital region of Denmark

Kliim-Hansen, V., Johansson, K. S., Gasbjerg, L. S., Jimenez-Solem, E., Petersen, T. S., Nyeland, M. E., Ellegaard, A.-M., Pedersen, M. G., Knop, F. K. & Christensen, M. B., 1 sep. 2023, I: *Diabetologia*. 66, SUPPL 1, 1, s. S488

Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach

Brønden, A., Christensen, M. B., Glintborg, D., Snorgaard, O., Kofoed-Enevoldsen, A., Madsen, G. K., Toft, K., Kristensen, J. K., Højlund, K., Hansen, T. K., Søndergaard, E. & Hansen, K. B., aug. 2023, I: *Diabetic medicine : a journal of the British Diabetic Association*. 40, 8, s. e15157 e15157.

Physician-led medication reviews in a type 2 diabetes outpatient clinic: a randomised trial

Johansson, S., Kornholt, J., Bulow, C., Petersen, T. S., Perrild, H., Rungby, J. & Christensen, M. B., 1 jul. 2023, I: *British Journal of Pharmacology*. 180, 1, s. 317 1 s.

Diabetes treatment for persons with severe mental illness: A registry-based cohort study to explore medication treatment differences for persons with type 2 diabetes with and without severe mental illness

Bakkedal, C., Persson, F., Kriegbaum, M., Andersen, J. S., Grant, M. K., Mohr, G. H., Lind, B. S., Andersen, C. L., Christensen, M. B., Siersma, V. & Rozing, M. P., 13 jun. 2023, I: *PLoS One*. 18, 6, e0287017.

The association between paracetamol dose/plasma concentration and the severity of methemoglobinemia: a case-control study

Petersen, T. S., Daoud, A., Bøgevig, S., Høgberg, L. C. G. & Christensen, M. B., 23 maj 2023, s. 117. 129 s.

Insulin kinetics in high dose insulin therapy—a human randomized controlled trial

Bøgevig, S., Petersen, T. S., Riis, T., Brønden, A., Praeger-Jahnsen, L., Friis-Hansen, L., Høgberg, L. C. G. & Christensen, M. B., 16 maj 2023, s. 85. 129 s.

Paracetamol medication errors are associated with a high risk of hepatotoxicity in children aged 0–6 years: a retrospective cohort study

Daoud, A., Gade, C., Bøgevig, S., Christensen, M. B., Dalhoff, K. P. & Petersen, T. S., 16 maj 2023, s. 47. 129 s.

Continuous renal replacement therapy (CRRT) removal capacity of selected pharmaceuticals in high concentrations, a whole blood (swine) in vitro model

Christensen, M. B., Høgberg, L. C. G., Hermann, D., Riis, T., Hannibal, J. & Bøgevig, S., maj 2023.

Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review

Baden, C. S., Andersen, J. T., Christensen, M. B. & Gade, C., 1 apr. 2023, I: *Adverse Drug Reaction Bulletin*. 339, 1, s. 1315-1318 4 s.

Physician-led medication reviews in polypharmacy patients treated with at least 12 medications in a type 2 diabetes outpatient clinic: A randomised trial

Johansson, K. S., Kornholt, J., Bülow, C., Petersen, T. S., Perrild, H., Rungby, J. & Christensen, M. B., apr. 2023, I: *Diabetic medicine : a journal of the British Diabetic Association*. 40, 4, s. e15052 e15052.

Protocol for assessing the effects of exogenous hormone administration on human postprandial glucose metabolism, appetite sensations, and food intake

Hagemann, C. A., Gasbjerg, L. S., Christensen, M. B. & Knop, F. K., 17 mar. 2023, I: *STAR Protocols*. 4, 1, 102070.

Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity

Jensen, T. L., Bronden, A., Karstoff, K., Christensen, M. B. & Sonne, D. P., mar. 2023, I: *Drugs of the Future*. 48, 3, s. 179-196 18 s.

Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial

Helsted, M. M., Gasbjerg, L. S., Vilsbøll, T., Nielsen, C. K., Forman, J. L., Christensen, M. B. & Knop, F. K., 27 feb. 2023, I: *BMJ Paediatrics Open*. 13, 2, e065736.

Medication review in hospitalised patients to reduce morbidity and mortality

Bülow, C., Clausen, S. S., Lundh, A. & Christensen, M., 23 jan. 2023, I: *Cochrane Database of Systematic Reviews*. 2023, 1, s. CD008986 CD008986.

Scoping Review of Randomized Trials With Discontinuation of Medicines in Older Adults

Kornholt, J., Bülow, C., Sørensen, A. M. S., Pressel, E., Petersen, T. S. & Christensen, M. B., dec. 2022, I: *Journal of the American Medical Directors Association*. 23, 12, s. 1926.e11-1926.e35 25 s.

Protocol for a 30-day randomised, parallel-group, non-inferiority, controlled trial investigating the effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19: the RASCOVID-19 trial

Kliim-Hansen, V., Gasbjerg, L. S., Ellegaard, A.-M., Lorentsson, H. J. N., Lynggaard, M. B., Hagemann, C. A., Legart, C., Mathiesen, D. S., Sivapalan, P., Jensen, J.-U. S., Vilsbøll, T., Christensen, M. B. & Knop, F. K., 30 nov. 2022, I: *BMJ Paediatrics Open*. 12, 11, s. e062895 8 s., e062895.

GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergman, N. C., Skov-Jepesen, K., Hartmann, B., Holst, J. J., Dela, F., Overgaard, J., Størling, J., Vilsbøll, T., Dejgaard, T. F., Havelund, J. F., Gorshkov, V., Kjeldsen, F., Færgeman, N. J. K., Madsen, M. R., Christensen, M. B. & Knop, F. K., 25 nov. 2022, I: *The Journal of clinical endocrinology and metabolism*. 107, 12, s. 3261-3274 14 s.

Evidensbaseret medicin

Christensen, M. B., 12 okt. 2022, *Evidensbaseret medicin*. Hammen, L. N. (red.). 1 udg. Bind 1. 560 s.

Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β -Cell Function in Patients With Type 2 Diabetes

Stensen, S., Gasbjerg, L. S., Rosenkilde, M. M., Vilsbøll, T., Holst, J. J., Hartmann, B., Christensen, M. B. & Knop, F. K., 1 okt. 2022, I: *Diabetes*. 71, 10, s. 2209-2221 13 s.

Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity

Stensen, S., Krogh, L. L., Sparre-Ulrich, A. H., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M., Christensen, M. B., Gasbjerg, L. S. & Knop, F. K., sep. 2022, I: *Diabetes, Obesity and Metabolism*. 24, 9, s. 1882-1887 6 s.

Endogenous glucose-dependent insulinotropic polypeptide (GIP) facilitates postprandial intestinal lipid uptake

Gasbjerg, L. S., Helsted, M. M., Stensen, S., Krogh, L. S. L., Sparre-Ulrich, A. H., Hartmann, B., Vilsbøll, T., Christensen, M. B., Holst, J. J., Christoffersen, C., Knop, F. K. & Rosenkilde, M. M., sep. 2022, I: *Diabetologia*. 65, SUPPL 1, s. S260-S260

Effects of a comprehensive medication review intervention on health-related quality of life and other clinical outcomes in geriatric outpatients with polypharmacy: A pragmatic randomized clinical trial

Kornholt, J., Feizi, S. T., Hansen, A. S., Laursen, J. T., Reuther, L. Ø., Petersen, T. S., Pressel, E. & Christensen, M. B., jul. 2022, I: *British Journal of Clinical Pharmacology*. 88, 7, s. 3360-3369 10 s.

Short-term mortality following tramadol poisonings in Denmark

Sørensen, A. M. S., Petersen, J., Christensen, M. B., Schelde, A. B., Andersen, J. T., Jimenez Solem, E. & Petersen, T. S., jul. 2022, I: *Basic and Clinical Pharmacology and Toxicology*. 131, 1, s. 83-92 10 s.

The Impact of Diabetes on Mortality and Clinical Outcomes in Hospitalized Patients with COVID-in the Capital Region of Denmark

KLIIM-HANSEN, V., Nyeland, M. E., Gasbjerg, L. S., Jimenez Solem, E., Petersen, T. S., Ellegaard, A. M., Knop, F. K. & Christensen, M. B., jun. 2022, I: *Diabetes*. 71, 1, 1217-P.

Drug use in patients with short bowel syndrome and intestinal failure

Vorre, M. M., Johansson, K. S., Fuglsang, K. A., Horwitz, H., Solem, E. J., Jeppesen, P. B. & Christensen, M. B., 28 apr. 2022, I: *Danish Medical Journal*. 69, 5

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Byberg, S., Skov-Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Vilsbøll, T., Christensen, M. B., Holst, B. & Knop, F. K., 19 apr. 2022, I: *Cell reports. Medicine*. 3, 4, s. 100582-100582.

Has the time come to stop routine N-acetylcysteine treatment in young children in Denmark? A review of 300 suspected paracetamol overdoses in children aged 0-6 years

Gade, C., Bøgevig, S., Daoud, A., Mathiesen, P. R., Christensen, M. B., Peder Dalhoff, K. & Petersen, T. S., mar. 2022, I: *Acta paediatrica*. 111, 3, s. 667-674 8 s.

VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center

Amos, B., Aurrecochea, C., Barba, M., Barreto, A., Basenko, E. Y., Bazant, W., Belnap, R., Blevins, A. S., Böhme, U., Brestelli, J., Brunk, B. P., Caddick, M., Callan, D., Campbell, L., Christensen, M. B., Christophides, G. K., Crouch, K., Davis, K., DeBarry, J. & Doherty, R. & 46 flere, Duan, Y., Dunn, M., Falke, D., Fisher, S., Flicek, P., Fox, B., Gajria, B., Giraldo-Calderón, G. I., Harb, O. S., Harper, E., Hertz-Fowler, C., Hickman, M. J., Howington, C., Hu, S., Humphrey, J., Iodice, J., Jones, A., Judkins, J., Kelly, S. A., Kissinger, J. C., Kwon, D. K., Lamoureux, K., Lawson, D., Li, W., Lies, K., Lodha, D., Long, J., MacCallum, R. M., Maslen, G., McDowell, M. A., Nabrzyski, J., Roos, D. S., Rund, S. S. C., Schulman, S. W., Shanmugasundram, A., Sitnik, V., Spruill, D., Starns, D., Stoeckert, C. J., Tomko, S. S., Wang, H., Warrenfeltz, S., Wieck, R., Wilkinson, P. A., Xu, L. & Zheng, J., 7 jan. 2022, I: *Nucleic Acids Research*. 50, D1, s. D898-D911

Glucagon Clearance is Preserved in Type 2 Diabetes

Grøndahl, M. F. G., Lund, A., Bagger, J. I., Petersen, T. S., Wewer Albrechtsen, N. J., Holst, J. J., Vilsbøll, T., Christensen, M. B. & Knop, F. K., jan. 2022, I: *Diabetes*. 71, 1, s. 73-82 10 s.

Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: a randomized, double-blind, placebo-controlled, crossover clinical trial

Heimbürger, S. M., Nielsen, C. N., Calanna, S., Holst, J. J., Vilsbøll, T., Knop, F. K. & Christensen, M. B., jan. 2022, I: *Diabetes, Obesity and Metabolism*. 24, 1, s. 142-147 6 s.

Acute changes in plasma glucose increases left ventricular systolic function in insulin-treated patients with type 2 diabetes and controls

Andersen, A., Jørgensen, P. G., Bagger, J. I., Baldassarre, M. P. A., Christensen, M. B., Pedersen-Bjergaard, U., Lindhardt, T. B., Gislason, G., Knop, F. K. & Vilsbøll, T., 2022, I: *Diabetes, Obesity and Metabolism*. 24, 6, s. 1123-1131 9 s.

Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes

Kim, A., Knudsen, J. G., Madara, J. C., Benrick, A., Hill, T. G., Abdul Kadir, L., Kellard, J. A., Mellander, L., Miranda, C., Lin, H., James, T., Suba, K., Spigelman, A. F., Wu, Y., MacDonald, P. E., Wernstedt Asterholm, I., Magnussen, T., Christensen, M., Vilsbøll, T. & Salem, V. & 4 flere, Knop, F. K., Rorsman, P., Lowell, B. B. & Briant, L. J., 17 nov. 2021, I: *eLife*. 10, e72919.

Exendin(9-39)NH₂ - recommendations for clinical use based on a systematic literature review

Gasbjerg, L. S., Bari, E. J., Christensen, M. B. & Knop, F. K., nov. 2021, I: *Diabetes, Obesity and Metabolism*. 23, 11, s. 2419-2436 18 s.

The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Hartmann, B., Holst, J. J., Vilsbøll, T., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., nov. 2021, I: *Diabetologia*. 64, 11, s. 2425-2431 7 s.

MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

Andersen, M. R., Suppli, M. P., Bagger, J. I., Christensen, M. B., Yosten, G. L. C., Knop, F. K. & Lund, A., 1 sep. 2021, I: *European Journal of Endocrinology*. 185, 4, s. R93-R101

Causes of discrepancies between medications listed in the national electronic prescribing system and patients' actual use of medications

Bülow, C., Noergaard, J. D. S. V., Faerch, K. U., Pontoppidan, C., Unkerskov, J., Johansson, K. S., Kornholt, J. & Christensen, M. B., sep. 2021, I: *Basic and Clinical Pharmacology and Toxicology*. 129, 3, s. 221-231 11 s.

Exogenous LEAP2 improves postprandial glucose tolerance and reduces ad libitum food intake in men

Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Christensen, M. B., Heimbürger, S. M. N., Dela, F., Vilsbøll, T., Holst, B. & Knop, F. K., sep. 2021, s. 23-23.

Exogenous secretin decreases ad libitum food intake and exhibits a biphasic effect on supraclavicular brown adipose tissue activity in healthy men

Bentzen, M. J., Heimbürger, S. M. N., Hartmann, B., Holst, J. J., Christensen, M. B. & Knop, F. K., sep. 2021, s. 211. 1 s.

Glucose-dependent insulinotropic polypeptide (GIP) contributes to sitagliptin-mediated improvement of beta cell function in patients with type 2 diabetes

Stensen, S., Gasbjerg, L. S., Rosenkilde, M. M., Hartmann, B., Vilsbøll, T., Holst, J. J., Christensen, M. B. & Knop, F. K., sep. 2021, s. 95-95.

Six-day sc GIP infusion increases plasma NEFA without altering the adipose tissue transcriptome, GIPR levels or plasma markers of inflammation in patients with type 1 diabetes

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Hartmann, B., Holst, J. J., Dela, F., Overgaard, J., Storling, J., Vilsbøll, T., Dejgaard, T. F., Pyke, C., Christensen, M. B. & Knop, F. K., sep. 2021, s. 258-258. 1 s.

Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo

Veedefald, S., Bergmann, N. C., Vilsbøll, T., Christensen, M. B., Holst, J. J. & Knop, F. K., aug. 2021, I: *Diabetic Medicine*. 38, 8, s. e14592 e14592.

Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

Andersen, A., Bagger, J. I., Baldassarre, M. P., Christensen, M. B., Abelin, K. U., Faber, J., Pedersen-Bjerrregaard, U., Holst, J. J., Lindhardt, T. B., Gislason, G. H., Knop, F. K. & Vilsbøll, T., 21 jul. 2021, I: *European Journal of Endocrinology*. 185, 2, s. 343-353 11 s.

Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity

Jepsen, M. M. & Christensen, M. B., 3 jul. 2021, I: *Expert Opinion on Emerging Drugs*. 26, 3, s. 231-243 13 s.

Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998-2018

Christensen, M. B., Jimenez-Solem, E., Ernst, M. T., Schmidt, M., Pottegård, A. & Grove, E. L., 30 jun. 2021, I: *Scientific Reports*. 11, 1, s. 13603 1 s.

Effects of Exogenous Secretin on Postprandial Plasma Glucose and Lipids and Gallbladder Motility and Hemodynamics in Man

Bentzen, M. J., Heimbürger, S. M. N., Hartmann, B., Holst, J. J., Christensen, M. B. & Knop, F. K., jun. 2021.

Exogenous Secretin Decreases Energy Intake and Exerts a Bimodular Effect on Postprandial Brown Adipose Tissue Activation in Man

Heimbürger, S. M. N., Bentzen, M. J., Hartmann, B., Holst, J. J., Christensen, M. B. & Knop, F. K., jun. 2021.

Glucose -Dependent Insulinotropic Polypeptide (GIP) Contributes Substantially to the Improved Beta -Cell Function during Sitagliptin Treatment in Persons with Type 2 Diabetes

Stensen, S., Gasbjerg, L. S., Rosenkilde, M. M., Hartmann, B., Vilsboll, T., Holst, J. J., Christensen, M. B. & Knop, F. K., jun. 2021.

Six-Day Subcutaneous GIP Infusion Increases Circulating Free Fatty Acids without Altering the Adipose Tissue Transcriptome, Adipocyte GIP Receptor Levels, or Circulating Inflammation Markers in Patients with Type 1 Diabetes

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Hartmann, B., Holst, J. J., Dela, F., Overgaard, A. J., Storling, J., Vilsboll, T., Dejgaard, T. F., Pyke, C., Christensen, M. B. & Knop, F. K., jun. 2021.

The Glucagonotropic Effect of GLP-2 during Hypoglycemia, Euglycemia, and Hyperglycemia in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Hansen, N. L., Magnussen, T., Holst, J. J., Hartmann, B., Christensen, M. B., Lund, A. & Knop, F. K., jun. 2021.

Effects of endogenous GIP in patients with type 2 diabetes

Stensen, S., Gasbjerg, L. S., Krogh, L. L., Skov-Jepesen, K., Sparre-Ulrich, A. H., Jensen, M. H., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M., Christensen, M. B. & Knop, F. K., 21 maj 2021, I: *European Journal of Endocrinology*. 185, 1, s. 33-45 13 s.

Medication errors in residential facilities based on Danish Poison Information Center inquiries

Bakkedal, C., Eriksen, K. R., Hansen, N. B., Petersen, T. S., Dalhoff, K. P., Bøgevig, S., Rizing, M. P. & Christensen, M. B., 28 apr. 2021, I: *Danish Medical Journal*. 68, 5, s. A11200800 A11200800.

An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight

Theilade, S., Christensen, M. B., Vilsbøll, T. & Knop, F. K., feb. 2021, I: *Diabetes, Obesity and Metabolism*. 23, S1, s. 17-35 19 s.

Identification and metabolic profiling of a novel human gut-derived LEAP2 fragment

Hagemann, C. A., Zhang, C., Hansen, H. H., Jorsal, T., Rigbolt, K. T. G., Madsen, M. R., Bergmann, N. C., Heimbürger, S. M. N., Falkenhahn, M., Theis, S., Breitschopf, K., Holm, S., Hedegaard, M. A., Christensen, M. B., Vilsbøll, T., Holst, B., Vrang, N., Jelsing, J. & Knop, F. K., feb. 2021, I: *The Journal of clinical endocrinology and metabolism*. 106, 2, s. e966-e981

Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH₂ on GIP actions in humans

Gasbjerg, L. S., Bari, E. J., Stensen, S., Hoe, B., Lanng, A. R., Mathiesen, D. S., Christensen, M. B., Hartmann, B., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., jan. 2021, I: *Diabetes, Obesity and Metabolism*. 23, 1, s. 68-74 7 s.

Anvendt klinisk farmakologi

Dalhoff, K. P. (Redaktør), Andersen, S. E. (Redaktør), Hellebek, A. H., Jürgens, G., Christensen, H. R., Holst, H., Andersen, J. T., Enghusen-Poulsen, H., Christensen, M. B., Horwitz, H., Harboe, K. M., Reuther, L. Ø., Christiansen, M. L. S., Nørgaard, M., Petersen, T. S. & Skov, K., 2021, 1 udg. FADL's Forlag. 260 s.

GIP peptide analogues: US Patent 10,968,266, 2021

Christensen, M. B. (Opfinder), 2021, Patentnr. 10968266

Systemisk toksicitet ved lokalanalgetika

Johansson, K. S., Høgeberg, L. C. G., Christensen, M. B., Petersen, T. S., Dalhoff, K. & Bøgevig, S., 14 dec. 2020, I: *Ugeskrift for Laeger*. 182, 51

Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

Gotfredsen, D. R., Vinther, S., Petersen, T. S., Cortes, R., Jensen, T. B., Jimenez-Solem, E. & Christensen, M. B., 1 dec. 2020, I: *Scientific Reports*. 10, 1, s. 4095 4095.

GIP(3-30)NH₂ - a tool for the study of GIP physiology

Lynggaard, M. B., Gasbjerg, L. S., Christensen, M. B. & Knop, F. K., dec. 2020, I: *Current Opinion in Pharmacology*. 55, s. 31-40 10 s.

Multidisciplinær håndtering af svær jernforgiftning som følge af suicidalforsøg

Petersen, S. M., Boysen, T., Svane, M. S. & Christensen, M. B., 9 nov. 2020, I: *Ugeskrift for Laeger*. 182, 46

A poison information centre can provide important assessment and guidance regarding medication errors in nursing homes: A prospective cohort study

Vinther, S., Bøgevig, S., Eriksen, K. R., Hansen, N. B., Petersen, T. S., Dalhoff, K. P. & Christensen, M. B., 4 nov. 2020, I: *Basic & clinical pharmacology & toxicology*.

High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial

Petersen, K. M., Bøgevig, S., Riis, T., Andersson, N. W., Dalhoff, K. P., Holst, J. J., Knop, F. K., Faber, J., Petersen, T. S. & Christensen, M. B., 3 nov. 2020, I: *Journal of the American Heart Association*. 9, 21, s. e016828

The role of endogenous GIP and GLP-1 in postprandial bone homeostasis

Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Bergmann, N. C., Stensen, S., Hartmann, B., Christensen, M. B., Holst, J. J., Vilsbøll, T., Rosenkilde, M. M. & Knop, F. K., nov. 2020, I: *Bone*. 140, s. 115553 115553.

What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline

Johansson, K. S., Sonne, D. P., Knop, F. K. & Christensen, M. B., nov. 2020, I: *Expert Opinion on Drug Discovery*. 15, 11, s. 1253-1265 13 s.

Medication-related experiences of patients with polypharmacy: a systematic review of qualitative studies

Eriksen, C. U., Kyriakidis, S., Christensen, L. D., Jacobsen, R., Laursen, J., Christensen, M. B. & Frølich, A., 6 sep. 2020, I: *BMJ Paediatrics Open*. 10, 9, s. e036158

Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

Jensen, M. E., Galli, A., Thomsen, M., Jensen, K. L., Thomsen, G. K., Klausen, M. K., Vilsbøll, T., Christensen, M. B., Holst, J. J., Owens, A., Robertson, S., Daws, L., Zanella, D., Gether, U., Knudsen, G. M. & Fink-Jensen, A., 1 sep. 2020, I: *Neurochemistry International*. 138, s. 104772 104772.

Glucose-dependent Insulinotropic Polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes

Christensen, M. B., Lund, A. B., Jørgensen, N. R., Holst, J. J., Vilsbøll, T. & Knop, F. K., 1 sep. 2020, I: Journal of the Endocrine Society. 4, 9, s. bvaa097 bvaa097.

Cardiovascular effects of high-dose glucagon: a randomised clinical trial

Petersen, K. M., Bøgevig, S., Riis, T., Andersson, N. A. W., Dalhoff, K. P., Holst, J. J., Knop, F. K., Faber, J., Petersen, T. S. & Christensen, M. B., sep. 2020, s. S231-S231.

Counterregulatory responses to hypoglycaemia in totally pancreatectomised patients

Baekdal, M., Lund, A., Baldassarre, M., Rose, K., Egholk, J., Christensen, M. B., Hansen, C. P., Storkholm, J. H., Faber, J., Hartmann, B., Holst, J. J., Vilsbøll, T. & Knop, F. K., sep. 2020, s. S95-S95.

GIP infusion in patients with type 1 diabetes seems to attenuate post-prandial glucose excursions after prandial insulin over-dose and physical activity

Hoe, B., Heimbürger, S. M. N., Gasbjerg, L. S., Lanng, A. R., Lynggaard, M. B., Hartmann, B., Holst, J. J., Vilsbøll, T., Lund, A., Engberg, S., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., sep. 2020, s. S117-S117.

Identification of a gut-derived LEAP2 fragment as a novel insulin secretagogue

Hagemann, C. A., Zhang, C., Jorsal, T., Rigbolt, K. T., Falkenhahn, M., Theis, S., Christensen, M., Vilsbøll, T., Vrang, N., Jelsing, J. & Knop, F. K., sep. 2020, s. S70-S70.

Six-day subcutaneous GIP infusion increases glycaemic time in range in patients with type 1 diabetes

Heimbürger, S. M., Hoe, B., Nielsen, C., Bergmann, N. C., Hartmann, B., Holst, J. J., Størling, J., Vilsbøll, T., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., sep. 2020, s. S73-S73.

The impact of acute glycaemic fluctuations on left ventricular systolic function in insulin-treated type 2 diabetes

Andersen, A., Jørgensen, P. G., Bagger, J. I., Baldassarre, M. P. A., Christensen, M., Abelin, K. U., Faber, J., Pedersen-Bjergaard, U., Holst, J. J., Lindhardt, T., Gislason, G., Knop, F. K. & Vilsbøll, T., sep. 2020, s. S429-S429.

Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

Loeppenthin, K., Dalton, S. O., Johansen, C., Andersen, E., Christensen, M. B., Pappot, H., Petersen, L. N., Thisted, L. B., Frølich, A., Mortensen, C. E., Lassen, U., Ørsted, J. & Bidstrup, P. E., sep. 2020, I: British Journal of Cancer. 123, 6, s. 1033-1040 8 s.

Sex and age differences among tramadol users in three Nordic countries

Schelde, A. B., Sørensen, A. M. S., Hindsø, M., Christensen, M. B., Jimenez-Solem, E. & Eriksson, R., 1 jul. 2020, I: Danish Medical Journal. 67, 7, s. 1-12 12 s., A06190336.

Prevalence of polypharmacy in Denmark

Kornholt, J. & Christensen, M. B., 1 jun. 2020, I: Danish Medical Journal. 67, 6

Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes

Andersen, A., Jørgensen, P. G., Bagger, J. I., S., Baldassarre, M. P. A., Christensen, M. B., Abelin, K. U., Pedersen-Bjergaard, U., Holst, J. J., Lindhardt, T. B., Knop, F. K. & Vilsbøll, T., jun. 2020.

Counterregulatory Responses to Hypoglycemia in Totally Pancreatectomized Patients

Baekdal, M., Lund, A. B., Baldassarre, M. P. A., Egholk, J. I., Rose, K., Hansen, C., Storkholm, J. H., Christensen, M. B., Hartmann, B., Faber, J., Holst, J. J., Vilsbøll, T. & Knop, F. K., jun. 2020.

Six-Day Subcutaneous GIP Infusion Increases Glycemic Time-in-Range in Patients with Type 1 Diabetes

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Hartmann, B., Holst, J. J., Størling, J., Vilsbøll, T., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., jun. 2020.

The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes

Hoe, B., Heimbürger, S. M. N., Gasbjerg, L. S., Lynggaard, M. B., Hartmann, B., Holst, J. J., Vilsbøll, T., Lund, A., Engberg, S., Dejgaard, T. F., Christensen, M. B. & Knop, F. K., jun. 2020.

Clinical pharmacology of imeglimin for the treatment of type 2 diabetes

Johansson, K. S., Brønden, A., Knop, F. K. & Christensen, M. B., 23 maj 2020, I: Expert Opinion on Pharmacotherapy. 21, 8, s. 871-882 12 s.

Glucose-dependent insulinotropic polypeptide is a pancreatic polypeptide secretagogue in humans

Veedfald, S., Vedtofte, L., Skov-Jepesen, K., Deacon, C. F., Hartmann, B., Vilsbøll, T., Knop, F. K., Christensen, M. B. & Holst, J. J., 1 mar. 2020, I: The Journal of clinical endocrinology and metabolism. 105, 3, s. E502-E510 dgz097.

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M. & Knop, F. K., mar. 2020, I: Peptides. 125, 170183.

GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., mar. 2020, I: The Journal of clinical endocrinology and metabolism. 105, 3, s. E725-E738 dgz175.

GIP and the gut-bone axis - physiological, pathophysiological and potential therapeutic implications

Stensen, S., Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Christensen, M. B. & Knop, F. K., mar. 2020, I: Peptides. 170197.

GIP's involvement in the pathophysiology of type 2 diabetes

Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T. & Knop, F. K., mar. 2020, I: Peptides. 125, 170178.

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B. & Knop, F. K., mar. 2020, I: Peptides. 125, 170174.

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., Lund, A. & Knop, F. K., mar. 2020, I: Diabetes Care. 43, 3, s. 588-596 9 s., dc190578.

GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH₂

Gasbjerg, L. S., Hartmann, B., Christensen, M. B., Lanng, A. R., Vilsbøll, T., Jørgensen, N. R., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., 1 jan. 2020, I: Bone. 130, 115079.

Analgesics use and withdrawal in people with dementia - a register-based Danish study and a systematic review

Sørensen, A. M. S., Tarp, S., Johannsen, P., Lolk, A., Bandak, E., Pedersen, H., Saxtrup, N., Kallehauge, H., Solem, E. J. & Christensen, M. B., dec. 2019, I: Danish Medical Journal. 66, 12, s. A5578

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion - A Review

Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T. & Knop, F. K., 22 aug. 2019, I: International Journal of Molecular Sciences. 20, 17, 4092.

Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Jørgensen, N. R., Jessen, L., Hartmann, B., Holst, J. J., Christensen, M. B., Vilsbøll, T. & Knop, F. K., jul. 2019, I: The Journal of clinical endocrinology and metabolism. 104, 7, s. 2953-2960 8 s.

Do callers to out-of-hours care misuse an option to jump the phone queue?

Ebert, J. F., Huijbers, L., Christensen, B., Lippert, F. K. & Christensen, M. B., jun. 2019, I: Scandinavian Journal of Primary Health Care. 37, 2, s. 207-217 11 s.

Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedefald, S., Stensen, S., Lannig, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., maj 2019, I: Diabetes. 68, 5, s. 906-917 12 s.

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T. & Knop, F. K., 1 apr. 2019, I: Diabetologia. 62, 4, s. 665-675 11 s.

Long term treatment with stimulant laxatives - clinical evidence for effectiveness and safety?

Noergaard, M., Traerup Andersen, J., Jimenez-Solem, E. & Bring Christensen, M., 31 jan. 2019, I: Scandinavian Journal of Gastroenterology. 54, 1, s. 27-34 8 s.

Two-bag intravenous N-acetylcysteine, antihistamine pretreatment and high plasma paracetamol levels are associated with a lower incidence of anaphylactoid reactions to N-acetylcysteine

Daoud, A., Dalhoff, K. P., Christensen, M. B., Bøgevig, S. & Petersen, T. S., 2019, I: Clinical toxicology (Philadelphia, Pa.). s. 698-704 7 s.

Ventrikelaspiration er meget sjældent indiceret ved forgiftninger

Bøgevig, S., Christensen, M. B., Petersen, J. A., Dalhoff, K. P., Petersen, T. S., Palmqvist, D. F. & Groth Høgberg, L. C., 3 dec. 2018, I: Ugeskrift for Læger. 180, 49

Response to: Letter to the Editor: Hemodynamic Effects of Glucagon - A literature Review

Meidahl Petersen, K., Bøgevig, S., Holst, J. J., Knop, F. K. & Christensen, M. B., 1 dec. 2018, I: The Journal of clinical endocrinology and metabolism. 103, 12, s. 4480-4481 2 s.

Polypharmacy and medication deprescribing: A survey among multimorbid older adults in Denmark

Schiøtz, M. L., Frølich, A., Jensen, A. K., Reuther, L., Perrild, H., Petersen, T. S., Kornholt, J. & Christensen, M. B., dec. 2018, I: Pharmacology Research & Perspectives. 6, 6, s. e00431

Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects

Demant, M., Bagger, J. I., Suppli, M. P., Lund, A., Gyldenløve, M., Hansen, K. B., Hare, K. J., Christensen, M., Sonne, D. P., Holst, J. J., Vilsbøll, T. & Knop, F. K., 28 nov. 2018, I: Metabolic Syndrome and Related Disorders. 16, 10, s. 530-536 6 s.

Effects of high-dose, intravenous lipid emulsion on laboratory tests in humans: a randomized, placebo-controlled, double-blind, clinical crossover trial

Petersen, K. M., Jørgensen, N. R., Bøgevig, S., Petersen, T. S., Jensen, T. B., Dalhoff, K. P. & Christensen, M. B., 27 nov. 2018, I: Clinical Chemistry and Laboratory Medicine. 56, 12, s. 2047-2057 11 s.

Outcomes following calcium channel blocker exposures reported to a poison information center

Christensen, M. B., Petersen, K. M., Bøgevig, S., Al-Gibouri, S., Jimenez-Solem, E., Dalhoff, K. P., Petersen, T. S. & Andersen, J. T., 27 nov. 2018, I: BMC pharmacology & toxicology. 19, 1, s. 78

Hemodynamic effects of intravenous, high-dose lipid emulsion with and without metoprolol infusion in healthy volunteers: a randomized clinical trial

Meidahl Petersen, K., Bøgevig, S., Petersen, T. S., Jensen, T. B., Dalhoff, K. P., Henriksen, T., Poulsen, H. E. & Christensen, M. B., 9 nov. 2018, I: Clinical Pharmacology and Therapeutics.

Mono- and co-activation of the GIP and GLP-1 receptors inhibits bone resorption

Bergmann, N., Lund, A., Heimbürger, S. M., Gasbjerg, L. S., Jørgensen, N. R., Jessen, L., Hartmann, B., Holst, J. J., Christensen, M., Vilsbøll, T. & Knop, F. K., 1 okt. 2018, I: *Diabetologia*. 61, suppl 1, s. S348-S348 1 s., 717.

Postprandial effects of individual and combined GIP and GLP-1 receptor antagonism in healthy subjects

Gasbjerg, L. S., Helsted, M. M., Sparre-Ulrich, A. H., Lanng, A. R., Stensen, S., Jakobsen, M. H., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., Rosenkilde, M. M. & Knop, F. K., 1 okt. 2018, I: *Diabetologia*. 61, suppl 1, s. S246-S246 1 s., 503.

The role of the incretins in the postprandial bone remodelling

Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Stensen, S., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., Rosenkilde, M. & Knop, F. K., 1 okt. 2018, I: *Diabetologia*. 61, Suppl 1, s. S221-S221 1 s., 449.

Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes

Nerild, H. H., Christensen, M. B., Knop, F. K. & Brønden, A., okt. 2018, I: *Expert Opinion on Drug Discovery*. 13, 12, s. 1161-1167 8 s.

General Practitioners' Barriers Toward Medication Reviews in Polymedicated Multimorbid Patients: How can a Focus on the Pharmacotherapy in an Outpatient Clinic Support GPs?

Laursen, J., Kornholt, J., Betzer, C., Petersen, T. S. & Christensen, M. B., 25 sep. 2018, I: *Health services research and managerial epidemiology*. 5, s. 2333392818792169

Cardiovascular effects of antidiabetic drugs

Sørensen, A. M. & Christensen, M. B., sep. 2018, I: *Drugs of Today*. 54, 9, s. 547-559 13 s.

Effect of a medicines management model on medication-related readmissions in older patients admitted to a medical acute admission unit-A randomized controlled trial

Graabaek, T., Hedegaard, U., Christensen, M. B., Clemmensen, M. H., Knudsen, T. & Aagaard, L., 7 aug. 2018, I: *Journal of Evaluation in Clinical Practice*.

A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Novel Treatment Options

Johansen, N. J. & Christensen, M. B., jun. 2018, I: *Basic & clinical pharmacology & toxicology*. 122, 6, s. 650-659 9 s.

Hemodynamic Effects of Glucagon - A Literature Review

Meidahl Petersen, K., Bøgevig, S., Holst, J. J., Knop, F. K. & Christensen, M. B., 1 maj 2018, I: *The Journal of clinical endocrinology and metabolism*. 103, 5, s. 1804-1812 8 s.

GIP(3-30)NH₂ is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study

Gasbjerg, L. S., Christensen, M. B., Hartmann, B., Lanng, A. R., Sparre-Ulrich, A. H., Gabe, M. B. N., Dela, F., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M. & Knop, F. K., feb. 2018, I: *Diabetologia*. 61, 2, s. 413-423 10 s.

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J. & Rosenkilde, M. M., feb. 2018, I: *Peptides*. 100, s. 173-181 9 s.

Important Aspects of Pharmacist-led Medication Reviews in an Acute Medical Ward

Bülow, C., Faerch, K. U., Armandi, H., Jensen, B. N., Sonne, J., Christensen, H. R. & Christensen, M. B., feb. 2018, I: *Basic & clinical pharmacology & toxicology*. 122, 2, s. 253-261 9 s.

Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre

Christensen, A. P., Boegevig, S., Christensen, M. B., Petersen, K. M., Dalhoff, K. P. & Petersen, T. S., feb. 2018, I: *Basic & clinical pharmacology & toxicology*. 122, 2, s. 293-298 6 s.

Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption independently of Insulin and Glycemia

Christensen, M. B., Lund, A., Calanna, S., Jørgensen, N. R., Holst, J. J., Vilsbøll, T. & Knop, F. K., 2018, I: *The Journal of clinical endocrinology and metabolism*. 103, 1, s. 288-294 7 s.

Quality of care for people with multimorbidity - a case series

Schiøtz, M. L., Høst, D., Christensen, M. B., Domínguez, H., Hamid, Y., Almind, M., Sørensen, K. L., Saxild, T., Holm, R. H. & Frølich, A., 18 nov. 2017, I: *BMC Health Services Research*. 17, 1, s. 745

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans

Gasbjerg, L. S., Lanng, A. R., Hartmann, B., Sparre-Ulrich, A. H., Dela, F., Christensen, M., Holst, J. J., Vilsbøll, T., Rosenkilde, M. & Knop, F. K., 14 sep. 2017. 1 s.

Increased liver fat content in totally pancreatectomised patients

Bagger, J. I., Lund, A., Albrechtsen, N. J. W., Christensen, M., Grøndahl, M., Hansen, C. P., Storkholm, J. H., Holst, J. J., Vilsbøll, T. & Knop, F. K., 14 sep. 2017.

The effects of GIP/GLP-1 receptor co-activation on appetite and food intake in overweight/obese subjects

Bergmann, N., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Christensen, M., Vilsbøll, T. & Knop, F. K., 12 sep. 2017. 1 s.

Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide

Brønden, A., Knop, F. K. & Christensen, M. B., jul. 2017, I: *Clinical Pharmacokinetics*. 56, 7, s. 719-731 13 s.

The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses

Blom, L. H., Martel, B. C., Larsen, L. F., Hansen, C. V., Christensen, M. P., Juel-Berg, N., Litman, T. & Poulsen, L. K., jul. 2017, I: *Allergy*. 72, 7, s. 1081-1090 10 s.

An adverse drug event manager facilitates spontaneous reporting of adverse drug reactions

Vinther, S., Klarskov, P., Borgeskov, H., Darsø, P., Christophersen, A. K., Borck, B., Christensen, C., Hansen, M. V., Halladin, N. M. L., Christensen, M. B., Harboe, K. M., Lund, M. & Jimenez-Solem, E., jan. 2017, I: *Danish Medical Bulletin (Online)*. 64, 1, s. A5315

Non-Insulin Parenteral Therapies

Vilsbøll, T., Christensen, M. & Knop, F. K., 2017, *Textbook of Diabetes*. s. 453

Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis

Andersen, S. E. & Christensen, M., nov. 2016, I: *British Journal of Clinical Pharmacology*. 82, 5, s. 1291-1302 12 s.

Higher Endogenous Glucose Production during OGTT vs Isoglycemic Intravenous Glucose Infusion

Lund, A., Bagger, J. I., Christensen, M., Grøndahl, M., van Hall, G., Holst, J. J., Vilsbøll, T. & Knop, F. K., 17 aug. 2016, I: *Journal of Clinical Endocrinology and Metabolism*. 101, 11, s. 4377-4384

Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65:585-597

Lund, A., Bagger, J. I., Wewer Albrechtsen, N. J., Christensen, M., Grøndahl, M., Hartmann, B., Mathiesen, E. R., Hansen, C. P., Storkholm, J. H., van Hall, G., Rehfeld, J. F., Hornburg, D., Meissner, F., Mann, M., Larsen, S., Holst, J. J., Vilsbøll, T. & Knop, F. K., jun. 2016

Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses

Sonne, D. P., Röhde, U., Christensen, M., Hansen, M., Brønden, A., Toräng, S., Rehfeld, J. F., Holst, J. J., Vilsbøll, T. & Knop, F. K., maj 2016, I: *Journal of Clinical Endocrinology and Metabolism*. 101, 5, s. 2076-83 8 s.

Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans

Christensen, M. B., apr. 2016, I: *Danish Medical Bulletin (Online)*. 63, 4, 19 s., B5230.

Searching for the physiological role of glucose-dependent insulinotropic polypeptide

Holst, J. J., Windeløv, J. A., Boer, G. A., Pedersen, J., Svendsen, B., Christensen, M., Torekov, S., Asmar, M., Hartmann, B. & Nissen, A., apr. 2016, I: Journal of Diabetes Investigation. 7 Suppl 1, s. 8-12 5 s.

Medication review in hospitalised patients to reduce morbidity and mortality

Christensen, M. & Lundh, A., 20 feb. 2016, I: Cochrane Database of Systematic Reviews. 2, s. CD008986 84 s.

Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors

Sparre-Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J. & Rosenkilde, M. M., jan. 2016, I: British Journal of Pharmacology. 173, 1, s. 27-38 12 s.

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Storgaard, H., Gluud, L. L., Bennett, C., Grøndahl, M. F., Christensen, M. B., Knop, F. K. & Vilsbøll, T., 2016, I: P L o S One. 11, 11, s. e0166125

N- and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor

Hansen, L. S., Sparre-Ulrich, A. H., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J. & Rosenkilde, M. M., 2016, I: British Journal of Pharmacology. 173, 5, s. 826-38

Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes

Christensen, M., Sparre-Ulrich, A. H., Hartmann, B., Grevstad, U., Rosenkilde, M. M., Holst, J. J., Vilsbøll, T. & Knop, F. K., nov. 2015, I: International journal of obesity (2005). 39, 11, s. 1651-4 4 s.

Behandling af håndledsbrud hos ældre

Christensen, M., Troelsen, A., Kold, S., Brix, M. & Ban, I., 17 aug. 2015, I: Ugeskrift for Laeger. 177, 34

Laktoseholdige lægemidler kan som hovedregel indtages af personer med laktoseintolerans

Vinther, S., Rumessen, J. J. & Christensen, M., 9 mar. 2015, I: Ugeskrift for Laeger. 177, V11140608, s. 2-5 4 s.

Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy

Brønden, A., Naver, S. V., Knop, F. K. & Christensen, M., 2015, I: Expert Opinion on Drug Metabolism & Toxicology. 11, 9, s. 1493-503 11 s.

Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes

Christensen, M., Calanna, S., Sparre-Ulrich, A. H., Kristensen, P. L., Rosenkilde, M. M., Faber, J., Purrello, F., van Hall, G., Holst, J. J., Vilsbøll, T. & Knop, F. K., 2015, I: Diabetes. 64, 1, s. 72-78

Glucagon and type 2 diabetes: the return of the alpha cell

Lund, A., Bagger, J. I., Christensen, M., Knop, F. K. & Vilsbøll, T., dec. 2014, I: Current Diabetes Reports. 14, 12, s. 555

Glucose-dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans

Nissen, A. G. B., Christensen, M., Knop, F. K., Vilsbøll, T., Holst, J. J. & Hartmann, B., 21 aug. 2014, I: The Journal of clinical endocrinology and metabolism. s. jc20142547

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus

Christensen, M., Miossec, P., Larsen, B. D., Werner, U. & Knop, F. K., 14 aug. 2014, I: Expert Opinion on Drug Discovery. s. 1-29 29 s.

Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease

Idorn, T., Knop, F. K., Jørgensen, M. B., Christensen, M., Holst, J. J., Hornum, M. & Feldt-Rasmussen, B., jul. 2014, I: The Journal of clinical endocrinology and metabolism. 99, 7, s. 2457-66 10 s.

Glucose-dependent insulinotropic polypeptide (GIP): Effects on insulin and glucagon secretion in humans

Christensen, M., 3 apr. 2014

Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in human

Bak, M. J., Wewer Albrechtsen, N. J., Pedersen, J. H., Hartmann, B., Christensen, M., Vilsbøll, T., Knop, F. K., Deacon, C. F., Dragsted, L. O. & Holst, J. J., apr. 2014, I: European journal of endocrinology / European Federation of Endocrine Societies. 170, 4, s. 529-538

Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care

Petersen, A. B., Andersen, S. E., Christensen, M. & Larsen, H. L., jan. 2014, I: Clinical toxicology (Philadelphia, Pa.). 52, 1, s. 39-43 5 s.

Ensembl Genomes 2013: scaling up access to genome-wide data

Kersey, P. J., Allen, J. E., Christensen, M., Davis, P., Falin, L. J., Grabmueller, C., Hughes, D. S. T., Humphrey, J., Kerhornou, A., Khobova, J., Langridge, N., McDowall, M. D., Maheswari, U., Maslen, G., Nuhn, M., Ong, C. K., Paulini, M., Pedro, H., Toneva, I. & Tuli, M. A. & 13 flere, Walts, B., Williams, G., Wilson, D., Youens-Clark, K., Monaco, M. K., Stein, J., Wei, X., Ware, D., Bolser, D. M., Howe, K. L., Kulesha, E., Lawson, D. & Staines, D. M., jan. 2014, I: Nucleic Acids Research. 42, Database issue, s. D546-52

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials

Storgaard, H., Gluud, L. L., Christensen, M., Knop, F. K. & Vilsbøll, T., 2014, I: B M J Open. 4, 8, s. e005378

Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients with Type 2 diabetes

Christensen, M., Calanna, S., Holst, J. J., Vilsbøll, T. & Knop, F. K., 10 dec. 2013, I: The Journal of clinical endocrinology and metabolism. s. jc20133644

Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T. & Knop, F. K., okt. 2013, I: Diabetes Care. 36, 10, s. 3346-52 7 s.

Lixisenatide for the treatment of type 2 diabetes

Brønden, A., Knop, F. K. & Christensen, M. B., sep. 2013, I: Drugs of Today. 49, 9, s. 537-53 17 s.

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations: pharmacokinetic and toxicological considerations

Jespersen, M. J., Knop, F. K. & Christensen, M., jan. 2013, I: Expert Opinion on Drug Metabolism & Toxicology. 9, 1, s. 17-29 13 s.

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus

Petersen, A. B. & Christensen, M., 2013, I: Diabetes, Metabolic Syndrome and Obesity. 6, s. 217-31 15 s.

Medication review in hospitalised patients to reduce morbidity and mortality

Christensen, M. & Lundh, A., 2013, I: Cochrane Database of Systematic Reviews. 2, s. CD008986

Region bruger medicingennemgange trods svag evidens

Lundh, A. & Christensen, M., 2013, I: Ugeskrift for læger. 175, s. 2741

Diabetes. Add-on to metformin in T2DM—linagliptin or glimepiride?

Christensen, M. & Knop, F. K., okt. 2012, I: Nature Reviews Endocrinology. 8, 10, s. 576-8 3 s.

Comment on: Gögebakan et al. Glucose-dependent insulintropic polypeptide reduces fat-specific expression and activity of 11 β -hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012;61:292-300

Knop, F. K. & Christensen, M., sep. 2012, I: Diabetes. 61, 9, s. e12

Glukagonlignende peptid 1-analoger i behandlingen af type 2-diabetes mellitus

Christensen, M., Vilsbøll, T. & Knop, F. K., 20 aug. 2012, I: Ugeskrift for Laeger. 174, 34, s. 1935; discussion 1935

The unobtainable placebo: control of independent clinical research by industry?

Christensen, M. & Knop, F. K., 7 jan. 2012, I: Lancet. 379, 9810, s. 30

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsbøll, T., Christensen, M., Junker, A. E., Knop, F. K. & Gluud, L. L., 2012, I: B M J. 344, s. d7771

Regulation of glucagon secretion by incretins

Holst, J. J., Christensen, M., Lund, A., De Heer, J. J. N., Svendsen, B. M., Kielgast, U. & Knop, F. K., okt. 2011, I: Diabetes, Obesity and Metabolism Online. 13 Suppl 1, s. 89-94 6 s.

Lixisenatide for type 2 diabetes mellitus

Christensen, M., Knop, F. K., Vilsbøll, T. & Holst, J. J., 1 apr. 2011, I: Expert Opinion on Investigational Drugs. 20, 4, s. 549-57 9 s.

Glucose-dependent insulintropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans

Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T. & Knop, F. K., 2011, I: Diabetes. 60, 12, s. 3103-9 7 s.

International or national publication of case reports

Lundh, A., Christensen, M. & Jørgensen, A. W., 2011, I: Danish Medical Bulletin. 58, 2, s. A4242

Malokoplaki i colon behandlet med sulfamethizol og trimetoprim

Christensen, M., Knuhtsen, S. & Knudsen, E., 2011, I: Ugeskrift for Laeger. 173, 7, s. 509-10 2 s.

The alpha-cell as target for type 2 diabetes therapy

Christensen, M., Bagger, J. I., Vilsbøll, T. & Knop, F. K., 2011, I: Review of Diabetic Studies. 8, 3, s. 369-81 13 s.

Therapy for obesity based on gastrointestinal hormones

Bagger, J. I., Christensen, M., Knop, F. K. & Vilsbøll, T., 2011, I: Review of Diabetic Studies. 8, 3, s. 339-47 9 s.

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes

Jimenez-Solem, E., Rasmussen, M. H., Christensen, M. & Knop, F. K., 1 dec. 2010, I: Current Opinion in Molecular Therapeutics. 12, 6, s. 790-7 8 s.

Glucagon-like peptide-2, but not glucose-dependent insulintropic polypeptide, stimulates glucagon release in patients with type 1 diabetes

Christensen, M., Knop, F. K., Vilsbøll, T., Aaboe, K., Holst, J. J., Madsbad, S. & Krarup, T., 9 aug. 2010, I: Regulatory Peptides. 163, 1-3, s. 96-101 6 s.

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

Christensen, M. & Knop, F. K., 1 apr. 2010, I: Current Diabetes Reports. 10, 2, s. 124-32 9 s.

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus

Christensen, M., Knop, F. K., Holst, J. J. & Vilsbøll, T., 1 aug. 2009, I: IDrugs : the investigational drugs journal. 12, 8, s. 503-13 11 s.

The hypothalamo-pituitary-adrenal axis in major affective disorder: a review

Christensen, M. V. & Kessing, L. V., 2001, I: *Nordic Journal of Psychiatry*. 55, 5, s. 359-63 5 s.